Chemoprophylaxis of colon cancer

Current Colorectal Cancer Reports

Volumn 2, Issue 1, 2006, Pages 13-19

  Reddy, Bandaru S ^a   Rao, Chinthalapally V ^b  

^a RUTGERS UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34247847292     PISSN: 15563790     EISSN: 15563804     Source Type: Journal    
DOI: 10.1007/s11888-006-0012-0     Document Type: Article

References (56)

1. Jamal A, Murray T, Ward E, Samuels A, et al.: Cancer statistics. CA Cancer J Clin 2005, 55:10-30.
2. World Cancer Research Fund and American Institute for Cancer Research: Panel on Food, Nutrition and Prevention. Washington DC: American Institute for Cancer Research; 1997.
3. Caygil CPJ, Charland SL, Lippin JA: Fat, fish and fish oil, and cancer. Br J Cancer 1996, 74:159-164.
4. Reddy BS: Omega-3 fatty acids in colorectal cancer prevention. Int J Cancer 2004, 112:1-7.
5. Rao CV, Hirose Y, Cooma I, Reddy BS: Modulation of experimental colon tumorigenesis by types and amounts of dietary fatty acids. Cancer Res 2001, 61:1927-1933.
6. Reddy BS, Maruyama H: Effect of dietary fish oil on azoxymethane-induced colon carcinogenesis in male F 344 rats. Cancer Res 1986, 46:3367-3370.
7. Thun MJ, Namboodiri MM, Heath CJ Jr: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991, 325:1593-1596.
8. Thun MJ, Namboodiri MM, Calle EE, et al.: Aspirin use and risk of fatal cancer. Cancer Res 1993, 53:1322-1327.
9. Giovannucci E, Rimm EB, Stampfer M, et al.: Aspirin use and risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994, 121:241-246.
10. Kune G, Kune S, Watson LF: Colorectal cancer risk, chronic ilnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988, 48:4399-4404.
11. Giardiello FM, Hamilton SR, Krush AJ, et al.: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993, 328:1313-1316.
12. Labayle D, Fischer D, Vielh P, et al.: Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991, 101:635-639.
13. Lynch HT, Thorson AG, Smyrk T: Rectal cancer after prolonged sulindac chemoprevention: a case report. Cancer 1995, 75:936-938.
14. Tonelli F, Valanzano R: Sulindac in familial adenomatous polyposis. Lancet 1993, 342:1120.
15. Ladenheim J, Garcia G, Titzer D, et al.: Effect of sulin-dac on sporadic colonic polyps. Gastroenterology 1995, 108:1083-1087.
16. Reddy BS: Carcinogen-induced colon cancer models for chemoprevention and nutritional studies. In Tumor Models in Cancer Research. Edited by Teicher BA. Totowa, NJ: Humana Press; 2002:183-191.
17. Narisawa T, Sato M, Tani M, et al.: Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin treatment. Cancer Res 1981, 41:1954-1957.
18. Narisawa T, Sato M, Sano M, Takahashi T: Inhibition of development of methylnitrosourea-induced rat colonic tumors by peroral administration of indomethacin. Gann 1982, 73:377-381.
19. Pollard M, Luckert PH: Prolonged anti-tumor effect of indomethacin on autochthonous intestinal tumors in rats. J Natl Cancer Inst 1983, 70:1103-1105.
20. Reddy BS, Maruyama H, Kelloff G: Dose-related inhibition of colon carcinogenesis by dietary piroxicam: a nonsteroidal anti-inflammatory drug, during different stages of rat colon tumor development. Cancer Res 1987, 47:5340-5346.
21. Reddy BS, Tokumo K, Kulkarni N, et al.: Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis 1992, 13:1019-1023.
22. Reddy BS, Rao CV, Rivenson A, Kelloff G: Inhibitory effect of aspirin on azoxymethane-induced colon carcinogen-esis in F 344 rats. Carcinogenesis 1993, 14:1493-1497.
23. Moorghen M, Ince P, Finney KJ, et al.: The effect of sulindac on colonic tumor formation in dimeth-ylhydrazine-treated mice. Acta Histochem 1990, 39(Suppl):195-199.
24. Skinner SA, Penney AG, O'Brien P: Sulindac inhibits the rate of growth and appearance of colon tumors in the rat. Arch Surg 1991, 126:1094-1096.
25. Kawamori T, Rao CV, Seibert K, Reddy BS: Chemopreven-tive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998, 58:409-412.
26. Reddy BS, Kawamori T, Lubet RA, et al.: Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process. Cancer Res 1999, 59:3387-3391.
27. Wargovich MJ, Chen CD, Harris C, et al.: Inhibition of aberrant crypt growth by non-steroidal anti-inflammatory agents and differentiation agents in the rat colon. Int J Cancer 1995, 60:515-519.
28. Reddy BS, Rao CV, Seibert K: Evaluation of cyclooxy-genase-2 inhibitor for potential chemopreventative properties in colon carcinogenesis. Cancer Res 1996, 56:4566-4569.
29. Takahashi M, Fukutake M, Yokota S, et al.: Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclooxygenase 2. J Cancer Res Clin Oncol 1996, 122:219-222.
30. Reddy BS, Hirose Y, Lubet R, et al.: Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000, 60:293-297.
31. Boolbol SK, Dannenberg AJ, Chadburn A, et al.: Cyclo-oxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996, 56:2556-2560.
32. Chiu CH, McEntee MF, Whelan J: Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis. Cancer Res 1997, 57:4267-4273.
33. Mahmoud NN, Dannenberg AJ, Mestre J, et al.: Aspirin prevents tumors in a murine model of familial adenomatous polyposis. Surgery 1998, 124:225-231.
34. Oshima M, Murai N, Kargman S, et al.: Chemoprevention of intestinal polyposis in the APC (Delta)716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001, 61:1733-1740.
35. Reddy BS, Rao CV: Colon cancers: a role for cyclooxygen-ase-2 specific non-steroidal anti-inflammatory drugs. Drugs Aging 2000, 16:329-334.
36. Jacoby RF, Seibert K, Cole CE, et al.: The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polypo-sis. Cancer Res 2000, 60:5040-5044.
37. Williams JL, Borgo S, Hasan I, et al.: Nitric-oxide releasing NSAIDs alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer prevention. Cancer Res 2001, 61:3285-3289.
38. Rao CV, Simi B, Cooma I, et al.: Chemoprevention of colonic aberrant crypt foci by nitric oxide (NO)-releasing NSAIDs [abstract]. Front Cancer Prev Res 2002, 1:D321.
39. Cooma I, Swamy MV, Patlolla JM, et al.: Chemopreven-tion of colon carcinogenesis by oleanolic acid and its analog in male F 344 rats and modulation of Inos and COX-2, and apoptosis in human colon Ht-29 cancer cells [abstract]. Am Assoc Cancer Res 2002, 40:819.
40. Rao CV, Rivenson A, Simi B, Reddy BS: Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 1995, 55:259-266.
41. Kawamori T, Lubet R, Steele VE, et al.: Chemopreventive effect of curcumin, a naturally-occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res 1999, 59:597-601.
42. Rao CV, Simi B, Reddy BS: Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci in the rat colon. Carcinogenesis 1993, 14:2219-2225.
43. Rao CV, Desai D, Rivenson A, et al.: Chemoprevention of colon carcinogenesis by phenlethyl-3-methylcaffeate. Cancer Res 1995, 55:2310-2315.
44. Rao CV, Desai D, Simi B, et al.: Inhibitory effects of caffeic acid esters on azoxymethane-induced biochemical changes and aberrant crypt foci formation in rat colon. Cancer Res 1993, 53:4182-4188.
45. Huang MT, Ma W, Yen P, et al.: Inhibitory effects of caffeic acid phenethyl ester (CAPE) on 12-O-tetradecanoylphor-bol-13-acetate-induced tumor promotion in mouse skin and the synthesis of DNA, RNA and protein in HeLa cells. Carcinogenesis 1996, 17:761-765.
46. Mahmoud NN, Carothers AM, Grunberger D, et al.: Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis. Carcinogenesis 2000, 21:921-927.
47. Xu YX, Pindolia KR, Janakiraman N, et al.: Curcumin inhibits IL1 alpha and TNF-alpha induction of AP-1 and NF-kappaB DNA-binding activity in bone marrow stromal cells. Hematopathol Mol Hematol 1998, 11:49-62.
48. Honn K V, Grossi IM, Steinert BW, et al.: Lipoxygenase regulation of membrane expression of tumor cell gly-coproteins and subsequent metastasis. Adv Prostaglandin Thromboxane Leukot Res 1989, 19:439-443.
49. Natarajan K, Singh S, Burke TR Jr, et al.: Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. 1996, 93:9090-9095.
50. Reddy BS, Rao CV: Chemoprevention of colon cancer by thiol and other organosulfur compounds. In Food Phytochemicals in Cancer Prevention I. Edited by Huang MT, Osawa T, Ho CT, Rosen RT. Washington, DC: American Chemical Society; 1994:164-172.
51. Reddy BS, Nayani J, Tokumo K, et al.: Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a non-steroidal anti-inflammatory drug with D, L-alpha-difluoromethy-ornithine: an ornithine decarboxylase inhibitor, in diet. Cancer Res 1990, 50:2562-2568.
52. Agarwal B, Rao CV, Bhendwal S, et al.: Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effect of sulindac. Gastroenterology 1999, 117:838-847.
53. Swamy MV, Cooma I, Reddy BS, Rao CV: Lamin B, caspase-3-activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: a novel approach in developing effective chemopreventive regimens. Int J Oncol 2002, 20:753-759.
54. Li H, Schut HA, Conran P, et al.: Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon. Carcinogenesis 1999, 20:425-430.
55. Reddy BS, Wang CX, Steele VG, et al.: Synergistic effects of the combination of low doses of aspirin or celecoxib with Lipitor against colon carcinogenesis: a promising chemoprevention strategy [Abstract]. Presented at the 96th Annual Meeting of the American Association for Cancer Research. April 16-20, 2005.
56. Reddy BS, Patlolla JM, Simi B, et al.: Prevention of colon cancer by low doses of celecoxib, a cyclooxygenase inhibitor, administered in diet rich in omega-3 polyun-saturated fatty acids. Cancer Res 2005, 65:8022-8027.